公开(公告)号：US20240148807A1

公开(公告)日：2024-05-09

申请号：US18406002

申请日：2024-01-05

Applicant: Kagoshima University

Inventor： Ken-ichiro KOSAI ,  Nobuhiro Ijichi

IPC: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

CPC classification number: A61K35/761 ,  A61P35/04 ,  C12N15/86 ,  C12N15/861

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.

公开(公告)号：US20240173381A1

公开(公告)日：2024-05-30

申请号：US18548807

申请日：2022-03-02

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Eriko MATSUDA

IPC: A61K38/18 ,  A61K48/00 ,  A61P3/10 ,  C12N15/86

CPC classification number: A61K38/1808 ,  A61K38/1833 ,  A61K48/0033 ,  A61P3/10 ,  C12N15/86 ,  C12N2750/14143

Abstract: The present invention provides a novel therapeutic means that is relatively low invasive and capable of exerting a desired therapeutic effect on diabetes including T1D. Specifically, an agent for protecting and/or regenerating a pancreatic β cell in a mammal with diabetes is provided, which contains a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF), wherein the agent is systemically administered. The aforementioned preparation in combination with a nucleic acid encoding hepatocyte growth factor (HGF) is also provided.

公开(公告)号：US20210008134A1

公开(公告)日：2021-01-14

申请号：US16758019

申请日：2018-11-08

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Nobuhiro IJICHI

IPC: A61K35/761 ,  A61K47/55 ,  C12N15/86 ,  A61P35/04

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.

公开(公告)号：US20230414718A1

公开(公告)日：2023-12-28

申请号：US18253651

申请日：2021-11-18

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Eriko MATSUDA

IPC: A61K38/18 ,  C12N15/86 ,  C07K14/475 ,  A61P3/10 ,  A61P1/18

CPC classification number: A61K38/1833 ,  C12N15/86 ,  C07K14/4753 ,  A61P3/10 ,  A61P1/18

Abstract: An agent for protecting and/or regenerating pancreatic β cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.

公开(公告)号：US20210138037A1

公开(公告)日：2021-05-13

申请号：US17137933

申请日：2020-12-30

Applicant: KAGOSHIMA UNIVERSITY

Inventor： Ken-ichiro KOSAI ,  Cin Khai NGIN ,  Tomoyuki TAKAHASHI

IPC: A61K38/18 ,  C12N15/86 ,  A61K48/00

Abstract: The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal.